Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-15

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for intramuscular or subcutaneous administration of 500,000 IU.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

NCT06118619

Respiratory Tuberculosis

RECRUITING

Interferon Gamma for Drug Resistant Tuberculosis

NCT00001407

Pneumonia Pulmonary Tuberculosis

COMPLETED PHASE2

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123

Tuberculosis AIDS-related Complex

COMPLETED PHASE2

The Correlate of Risk Targeted Intervention Study

NCT02735590

Tuberculosis

UNKNOWN PHASE2/PHASE3

Efficacy and Safety of Intravenous Treatment of Tuberculosis

NCT04150367

Tuberculosis, Pulmonary

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open prospective observational cohort study. During the recruitment phase, a preliminary assessment of eligibility and non-inclusion criteria will be carried out.

Subject to prior compliance with all inclusion criteria and none of the exclusion criteria, after signing a voluntary informed consent, the patient will be included in the study.

Patients will be divided into groups, depending on the therapy prescribed to them as part of routine clinical practice (according to clinical guidelines):

Group 1:

Pathogenetic therapy with the use of the drug Ingaron + basic anti-tuberculosis therapy in accordance with approved clinical guidelines.

Group 2:

Basic anti-tuberculosis therapy in accordance with approved clinical guidelines.

When a patient is included in the study (Visit 0), an initial examination will be carried out, in accordance with generally accepted principles of treatment monitoring, which includes: history taking, physical examination, registration of vital signs, ECG, blood samples for general clinical, biochemical analysis, general analysis urine, bacteriological examination by sputum smear microscopy and sputum culture on dense nutrient media with drug sensitivity assessment, computed tomography and chest radiography.

The inclusion/exclusion criteria will be checked. The expected duration of the study for each patient will be no more than 204 days.

After the start of therapy, patients will be recorded monthly with physical examination data with registration of vital signs, general clinical, biochemical analyzes, urinalysis, smear microscopy and sputum culture. X-ray examination and clinical evaluation of effectiveness will be carried out every 2 months. At visit 7 (after 6 months from the start of therapy), an evaluation of computed tomography and chest x-ray in dynamics with an assessment of the effectiveness of therapy, as well as ECG, physical examination with registration of vital signs, general clinical, biochemical analyzes, general urinalysis, smear microscopy and culture of sputum.

At visits 1, 4 and 7 immunological parameters will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Ingaron + basic TB therapy 500,000 IU once daily for 3 months followed by 3 months follow-up

Interferon-Gamma

Intervention Type DRUG

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

No Intervention

only basic anti-tuberculosis therapy

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ingaron Interferon gamma human recombinant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or non-pregnant women 18-75 years of age.
* For women of childbearing age who are fertile: Agree to completely abstain from sexual intercourse or use dual methods of contraception to prevent pregnancy while participating in the study.
* Verified diagnosis of pulmonary tuberculosis (infiltrative tuberculosis, fibrous-cavernous tuberculosis in the infiltration phase).
* A positive sputum smear microscopy test result for acid-fast bacterium, assessed as moderate (++) or massive bacterial excretion (+++) no earlier than 30 days prior to enrollment in the study.
* Established resistance of the isolated pathogen to at least rifampicin, determined by molecular genetic or cultural methods for determining drug susceptibility.
* Prescribing the current baseline chemotherapy regimen according to clinical guidelines no earlier than 14 days prior to enrollment in the study.
* Compliance with prescribed therapy.
* No concomitant immunotherapy, or 6 months from the last dose of an immunomodulatory drug to the start of therapy.
* Absence of comorbidities and therapy that may affect the interpretation of study results, in the opinion of the investigator.
* Signed written informed consent to participate in the study.
* Willingness and ability to follow protocol requirements throughout the study.

Exclusion Criteria

* For women: pregnant, breastfeeding or planning a pregnancy during the study period.
* Caseous pneumonia.
* Asthma, with the exception of mild intermittent asthma.
* Systemic fungal infections.
* Use of any investigational drug within 30 days prior to screening.
* Oncological diseases (cytotoxic chemotherapy, current or received within the last 3 months before the start of treatment).
* Chronic diseases of the liver or kidneys (an increase in liver transaminases more than 5 times the upper limit of laboratory norms for these indicators; an increase in creatinine above 2 mg / 100 ml (or μmol / l)).
* Diabetes.
* HIV infection or other immunodeficiency conditions.
* Inability, in the opinion of the investigator, to comply with the treatment regimen and the requirements of the study protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No